Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2025-09-16 00:00:00 ET · period of report 2025-09-12 · accession 0001899977-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-16 | 2025-09-12 | ACAD | Schneyer Mark C. | EVP, CFO | A - Grant | $0.00 | +6,815 | 46.9K | +17% | $0 | |
| 2025-09-16 | 2025-09-15 | ACAD | Schneyer Mark C. | EVP, CFO | S - Sale | $23.65 | -3,498 | 43.4K | -7% | -$82.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-12 | A | A | 6,815 | $0.00 | 46,945 | D | — | — | (F1) Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024, the performance stock units have vested at 75% of target. |
| 2 | Common | Common Stock | 2025-09-15 | S | D | 3,498 | $23.65 | 43,447 | D | — | — |